IL22 and polycystic ovary syndrome: To clarify the role of IL-22 in a non-metabolic PCOS mouse model, we further administered IL-22 to mice in the DHEA + rosiglitazone group and found that the estrous cycle alternated regularly after IL-22 treatment (Fig. 2A).